Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Completed · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
This study will evaluate the safety and tolerability of CR011-vcMMAE in patients with locally advanced and metastatic breast cancer. CR011-vcMMAE will be administered intravenously (IV) once every 3 weeks (q3w) to cohorts of 3-6 patients to confirm the maximum tolerated dose (MTD) in breast cancer patients. Once the MTD is confirmed, up to 25 patients with locally advanced or metastatic breast cancer will be enrolled into the Phase II portion of the trial to further evaluate the safety and efficacy of CR011-vcMMAE.
Key facts
- Study ID
- NCT00704158
- Run by
- CuraGen Corporation
- People needed
- 42
- Starts
- 2008-06-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2015-02-19
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Hematology Oncology Associates — Lake Worth, Florida, United States
- Georgia Cancer Specialists — Atlanta, Georgia, United States
- Cornell University — New York, New York, United States
- Tennessee Oncology — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.